# Cagrilintide Research Overview: What Studies Show About This Amylin Analog > A plain look at what clinical trials actually show about cagrilintide, an amylin analog studied alone and paired with semaglutide. - URL: https://www.lifeconverted.com/learn/cagrilintide-research-overview-what-studies-show-about-this-amylin-analog - Category: Longevity & Wellness - Author: Amara Diallo, Science Communicator - Published: 2026-09-23 - Updated: 2026-09-25 - Reading time: 4 min - Keywords: cagrilintide research, cagrilintide semaglutide, amylin analog, cagrisema trial results --- Your pancreas releases two hormones after a meal, not one. Insulin gets all the attention, but a smaller partner called amylin rides along with it, telling your brain that you have had enough to eat and that your stomach can slow down. For decades that second signal was mostly a footnote in metabolic research. Then scientists built a long acting version of it, gave it a name, and started testing it alongside the GLP-1 drugs that changed weight management. That compound is cagrilintide, and this article walks through what the published trials actually found. ## What cagrilintide is and how it differs from GLP-1 receptor agonists [Cagrilintide](/peptides/cagrilintide) is a synthetic amylin analog. Chemists modified the natural amylin peptide and attached a fatty acid chain to it, the same trick used to extend the action of semaglutide, so that the compound stays active in the body for about a week instead of minutes. The engineering work behind this design is described in detail by [Kruse and colleagues](https://pubmed.ncbi.nlm.nih.gov/34288673/), who developed cagrilintide specifically to give amylin the long acting profile that made once weekly GLP-1 drugs practical. The distinction matters because amylin and GLP-1 are not the same signal wearing different clothes. GLP-1 receptor agonists like semaglutide slow digestion and blunt appetite through incretin pathways in the gut and brain. Amylin analogs work through a separate receptor system that also affects appetite, but does so partly by acting on brain regions tied to satiety and partly by slowing how fast the stomach empties. A [network meta analysis by Yao and colleagues](https://pubmed.ncbi.nlm.nih.gov/38286487/) comparing GLP-1 receptor agonists for glycemic control and weight found meaningful differences between individual drugs in this class, which is a reminder that even within one pathway, molecules behave differently. Amylin analogs sit outside that pathway entirely, which is the whole reason researchers got interested in combining them. ## The amylin pathway and its role in appetite regulation and gastric emptying Amylin is not a new discovery. Researchers first isolated it decades ago, and its biology has been mapped slowly since then. A useful summary of that history comes from [Lutz](https://pubmed.ncbi.nlm.nih.gov/35183619/), who traces how amylin research evolved from a minor pancreatic hormone into a serious target for obesity treatment. Here is the short version. When you eat, amylin is released from the same beta cells that release insulin. It travels to the brainstem and acts on receptors there to reduce food intake, and it also slows gastric emptying, meaning food stays in the stomach longer and signals fullness for a longer stretch of time. In people with obesity or type 2 diabetes, this signal can be blunted, similar to how insulin resistance blunts insulin's effect. The logic behind cagrilintide is straightforward: restore a stronger version of that fullness signal, and appetite drops along with it. This is also why nausea and slowed digestion show up as common side effects in amylin analog trials. The mechanism that reduces intake is the same one that makes the stomach feel fuller for longer, so some digestive discomfort is an expected part of how the compound works, not a separate problem layered on top. ## Key preclinical and clinical findings on body weight and metabolic markers The clearest human data on cagrilintide alone comes from a phase 2 dose finding trial published in [Lau and colleagues in the Lancet](https://pubmed.ncbi.nlm.nih.gov/34798060/). This randomized, double blind, placebo and active controlled study tested several cagrilintide doses in adults with overweight or obesity over 26 weeks. Higher doses produced greater weight reduction than placebo, and the effect scaled with dose in a fairly predictable way. Gastrointestinal side effects, mostly nausea and constipation, were the most common adverse events, and they tended to ease as the trial went on. That single trial does not tell the whole story on its own, which is where a systematic review helps. [Dutta and colleagues](https://pubmed.ncbi.nlm.nih.gov/39676787/) pooled results across cagrilintide studies, both as a standalone treatment and in combination with semaglutide under the research name CagriSema, and found consistent weight loss effects across the pooled data, with the combination generally outperforming either compound studied alone. Reviews like this are useful because a single trial can be shaped by its specific population or dosing schedule, while a pooled analysis smooths some of that variability out, though it inherits the limitations of whatever trials it includes. ## How cagrilintide is being studied in combination with semaglutide The bigger story in cagrilintide research is not the compound by itself. It is what happens when researchers pair it with semaglutide, since the two act on different pathways and might produce an additive effect rather than a redundant one. Early groundwork for this idea came from a phase 1b trial by [Enebo and colleagues](https://pubmed.ncbi.nlm.nih.gov/33894838/), which tested the safety, tolerability, and pharmacokinetics of cagrilintide given alongside semaglutide 2.4 mg. The combination was generally well tolerated, with a side effect profile similar to what each compound produced individually, and the pharmacokinetic data showed no unexpected interaction between the two. That safety groundwork opened the door to efficacy testing. A phase 2 trial in people with type 2 diabetes, published by [Frias and colleagues](https://pubmed.ncbi.nlm.nih.gov/37364590/), found that once weekly cagrilintide 2.4 mg combined with once weekly semaglutide 2.4 mg produced greater reductions in both blood glucose markers and body weight than semaglutide alone. That combination result is what pushed the research into larger phase 3 trials. Those phase 3 trials, both published in 2025 in the New England Journal of Medicine, are the most substantial data available so far. [Garvey and colleagues](https://pubmed.ncbi.nlm.nih.gov/40544433/) studied coadministered cagrilintide and semaglutide in adults with overweight or obesity, and [Davies and colleagues](https://pubmed.ncbi.nlm.nih.gov/40544432/) ran a parallel trial in adults with overweight or obesity who also had type 2 diabetes. Across both populations, the combination produced meaningfully greater weight loss than semaglutide alone, alongside improvements in metabolic markers such as blood glucose control in the diabetes trial. Side effects were largely gastrointestinal and consistent with what earlier phase trials had already shown, which suggests the tolerability profile holds up as the studies scale. A separate review by [Panou and colleagues](https://pubmed.ncbi.nlm.nih.gov/39317404/) puts this development in context by looking at amylin analogs for obesity treatment specifically in people without diabetes, and it frames cagrilintide as part of a broader wave of amylin based research that is still working out where this pathway fits relative to established GLP-1 therapy. ## Current research limitations and open questions for future studies None of this makes cagrilintide a finished product. A few honest caveats are worth sitting with. First, cagrilintide has not been approved by the FDA on its own, and the combination product with semaglutide is still working through the regulatory process based on the trials above. Nothing here should be read as describing an approved treatment. Second, most trial durations run in the range of six months to just over a year. Longer term data on durability of weight loss, what happens after stopping the compound, and rare long term side effects are still limited compared to what exists for older obesity drugs. Third, trial populations skew toward adults with overweight, obesity, or type 2 diabetes who meet fairly specific enrollment criteria. How the combination performs in broader populations, including people with other chronic conditions or on other medications, is less well mapped. Fourth, amylin analogs as a class are newer to large scale human trials than GLP-1 receptor agonists, so the safety database is smaller by comparison, even though what exists so far looks consistent across studies. If you are trying to compare compounds or just want a single reference point for dosing math on research compounds generally, the [LifeConverted calculator](/calculator) and the [full peptide library](/all-peptides) are built for exactly that kind of side by side lookup. ## Common questions **Is cagrilintide approved for weight loss?** Not yet on its own. It is an investigational amylin analog being studied in combination with semaglutide, and it has not received FDA approval as of the trials cited here. **How is cagrilintide different from semaglutide?** Semaglutide mimics GLP-1, while cagrilintide mimics amylin. They act on different receptors and different appetite pathways, which is why researchers are testing them together. **What is CagriSema?** CagriSema is the research name for the combined once weekly injection of cagrilintide and semaglutide studied in phase 3 trials for weight management and type 2 diabetes. *This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.* ## FAQ ### Is cagrilintide approved for weight loss? Not yet on its own. It is an investigational amylin analog being studied in combination with semaglutide, and it has not received FDA approval as of the trials cited here. ### How is cagrilintide different from semaglutide? Semaglutide mimics GLP-1, while cagrilintide mimics amylin. They act on different receptors and different appetite pathways, which is why researchers are testing them together. ### What is CagriSema? CagriSema is the research name for the combined once weekly injection of cagrilintide and semaglutide studied in phase 3 trials for weight management and type 2 diabetes. ## Sources - Garvey WT et al., 2025, N Engl J Med: https://pubmed.ncbi.nlm.nih.gov/40544433/ - Davies MJ et al., 2025, N Engl J Med: https://pubmed.ncbi.nlm.nih.gov/40544432/ - Lau DCW et al., 2021, Lancet: https://pubmed.ncbi.nlm.nih.gov/34798060/ - Frias JP et al., 2023, Lancet: https://pubmed.ncbi.nlm.nih.gov/37364590/ - Kruse T et al., 2021, J Med Chem: https://pubmed.ncbi.nlm.nih.gov/34288673/ - Enebo LB et al., 2021, Lancet: https://pubmed.ncbi.nlm.nih.gov/33894838/ --- Published by LifeConverted, https://www.lifeconverted.com/learn/cagrilintide-research-overview-what-studies-show-about-this-amylin-analog